Biotech Startups

Minafin is a chemicals company; no other details are provided on this page.

1 investor

MiNA Therapeutics develops small activating RNA (RNAa) therapeutics, a new class of medicines designed to restore or enhance gene function for treating genetic diseases and other conditions. The company has a platform approach that advances proprietary drug candidates and collaborates with pharmaceutical companies across multiple therapeutic areas.

1 investor

Mind Emulation Foundation funds and conducts scientific research focused on advancing the technical feasibility of emulating human minds digitally via connectome mapping and digital reconstruction. The organization works toward making mind emulation technology accessible to the general public.

1 investor

1 investor

Definium Therapeutics is a biotech company developing psychedelic-based treatments for brain health disorders, including formulations of LSD and MDMA enantiomers targeting depression, anxiety, PTSD, and autism spectrum disorder. Its pipeline focuses on psychiatric and neurological conditions affecting patients in the U.S.

1 investor

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system disorders. It focuses on designing clinical trials with endpoints tied to patient benefit.

1 investor

SCHOTT MINIFAB provides contract design, development, and manufacturing services for life science research and diagnostic consumables, including cleaned and coated substrates for in vitro diagnostics and research applications. It specializes in microarray, microfluidic, and injection molding techniques and serves product developers in the diagnostics and life science tools market, with production in the United States, Germany, and Australia.

1 investor

Minutia develops insulin-producing cell transplants that can be monitored in vivo over time, aimed at improving cell replacement therapy for diabetes. The company works in the regenerative medicine and cell therapy field.

1 investor

Miphic provides imaging-based diagnostic screening of mitochondrial function to identify drug efficacy and personalized treatment options for cancer, neurodegenerative disease, diabetes, and aging-related conditions. The platform screens up to 96 conditions simultaneously to support drug discovery, personalized medicine selection, and metabolic research.

1 investor

MiraBiologics is a Japanese biopharmaceutical drug discovery company that uses its LassoGraft Technology to graft cyclic peptides onto scaffold proteins for the development of novel biologics. It pursues collaborative R&D partnerships to create innovative biopharmaceuticals.

1 investor

Miracle unifies data from multiple clinical trial platforms to provide automated insights for healthcare professionals in biopharma. The company aims to accelerate clinical trial execution and help bring new therapeutics to market more efficiently.

1 investor

MFC Co., Ltd. manufactures active pharmaceutical ingredients (APIs) and key starting materials, and conducts R&D and mass production in pharmaceuticals and materials. Using high-purity crystallization technology, it develops and supplies Statin-class APIs such as TBFA and TPPBr, focusing on domestic production of imported pharmaceutical ingredients in South Korea.

1 investor

Miramoon Pharma develops neuroprotective small molecule therapies targeting degenerative disorders including ophthalmology, skeletal and cardiac muscle diseases, and central nervous system conditions. The company was spun out from the University of the Basque Country and Biogipuzkoa Health Research Institute.

1 investor

Miraqules develops biomaterial-based wound healing products for point-of-care medical applications. The company creates affordable, fast-acting solutions including products like StopBleed and InstaBrin, targeting the global healthcare market.

1 investor

Mirata Pharmaceuticals is developing pain-relieving drugs intended to provide the analgesic benefits of opioids without their addictive properties and serious side effects. It targets patients and physicians seeking safer alternatives to prescription opioids.

1 investor

Mireca develops treatments for rare, inherited retinal degenerations based on scientific research originating from the EU-funded DRUGSFORD project. The company translates basic research into therapeutic candidates targeting photoreceptor degeneration diseases such as retinitis pigmentosa and achromatopsia.

1 investor

1 investor

Miromatrix develops fully biologic organs using decellularization and recellularization technology for transplant patients. The company focuses on engineering transplantable kidneys, livers, and liver support devices to address the critical shortage of donor organs.

1 investor

Mirror Physics offers Axon, a software product for drug discovery workflows that integrates with a team's existing tools, data, and infrastructure to surface insights and handle pipeline tasks. It targets drug discovery and pharmaceutical research teams.

1 investor

MISO Chip develops microfluidic systems and diagnostic technologies for oncology, drug development, and precision medicine applications. The company serves biologists, physicians, and clinical researchers seeking to accelerate the translation of biomedical discoveries into patient treatments.

1 investor

MIT Life Sciences Angels is an angel investment group affiliated with MIT that focuses on funding life sciences and biotechnology startups, led by experienced entrepreneurs and venture investors.

1 investor

1 investor

Mitotherapeutix develops siRNA-based drugs using RNA silencing to target disease-related genes, with an initial focus on a protein that regulates mitochondrial metabolic activity. The company aims to create therapies that treat a range of diseases by controlling this metabolic regulator.

1 investor

Mitrix Bio develops bioreactor-grown young mitochondria encased in extracellular vesicles ("Mitlets") intended for transplantation to supplement aging cells. The company targets mitochondrial dysfunction implicated in age-related diseases such as Alzheimer's, retinal disease, liver dysfunction, and immune senescence.

1 investor